Beam Therapeutics Inc. (BEAM)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
John Evans
Employees:
510
26 LANDSDOWNE STREET, CAMBRIDGE, MA 02139
857-327-8775

Beam Therapeutics Inc. develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.

Data derived from most recent annual or quarterly report
Market Cap 2.237 Billion Shares Outstanding79.2 Million Avg 30-day Volume 1.581 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1.22
Price to Revenue23.3041 Debt to Equity0.0 EBITDA-363.793 Million
Price to Book Value2.4399 Operating Margin-488.4224 Enterprise Value885.086 Million
Current Ratio4.717 EPS Growth0.044 Quick Ratio4.608
1 Yr BETA 1.897 52-week High/Low 51.6 / 16.95 Profit Margin-384.62
Operating Cash Flow Growth-477.837 Free Cash Flow to Firm (FCFF) TTM -422.391 Million Free Cash Flow to Equity (FCFE) TTM-315.024 Million
Altman Z-Score0.7006
Earnings Report2024-02-27

Are you looking for this stock instead?

View SEC Filings from BEAM instead.

View recent insider trading info

Beam Therapeutics Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding BEAM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BEAM

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-11-22 by BELLON CHRISTINE
  • 4: filed on 2023-11-01 by SIMON AMY
  • 4: filed on 2023-10-24 by CIARAMELLA GIUSEPPE
  • 4: filed on 2023-10-04 by BELLON CHRISTINE
  • 4: filed on 2023-08-09 by SIMON AMY
  • 4: filed on 2023-07-25 by CIARAMELLA GIUSEPPE
  • 4: filed on 2023-06-08 by FISHMAN MARK
  • 4/A: filed on 2023-04-19 by BURRELL TERRY-ANN
  • 4: filed on 2023-04-05 by EVANS JOHN M.
  • 4: filed on 2023-04-05 by CIARAMELLA GIUSEPPE

    • Events (8k)

  • 8-K: filed on 2023-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-31:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-19:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-08:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-10:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-07-21:
  • 144: filed on 2023-10-30:
  • 144: filed on 2023-11-20:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    13.4 Thousand total shares from 3 transactions

    Exercise Derivative Conversion (M)

    100.9 Thousand total shares from 3 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BELLON CHRISTINE CHIEF LEGAL OFFICER

    • Officer
    		 82,402 2023-11-20 5

    SIMON AMY CHIEF MEDICAL OFFICER

    • Officer
    		 65,469 2023-10-30 5

    CIARAMELLA GIUSEPPE PRESIDENT AND CSO

    • Officer
    		 139,150 2023-10-20 8

    MARAGANORE JOHN

    • Director
    		 0 2023-06-06 1

    COOPER GRAHAM K

    • Director
    		 0 2023-06-06 1

    BUROW KRISTINA

    • Director
    		 5,469,050 2023-06-06 1

    WALSH KATHLEEN E

    • Director
    		 0 2023-06-06 1

    HO CAROLE

    • Director
    		 0 2023-06-06 1

    FISHMAN MARK

    • Director
    		 0 2023-06-06 1

    EVANS JOHN M. CEO

    • Officer
    • Director
    		 2,345,451 2023-04-03 2

    BURRELL TERRY-ANN CHIEF FINANCIAL OFFICER

    • Officer
    		 47,117 2023-04-03 6

    FMR LLC

    • 10% Owner
    • SEE REMARK 1
    		 4,938,538 2022-09-06 0

    ARCH VENTURE PARTNERS IX, LLC

    ARCH VENTURE PARTNERS IX, L.P.

    ARCH VENTURE PARTNERS IX OVERAGE, L.P.

    ARCH VENTURE FUND IX, L.P.

    ARCH VENTURE FUND IX OVERAGE, L.P.

    CRANDELL KEITH

    BYBEE CLINTON

    NELSEN ROBERT

    • 10% Owner
    		 No longer subject to file 2021-06-30 0

    ARCH VENTURE PARTNERS IX, LLC

    ARCH VENTURE PARTNERS IX, L.P.

    ARCH VENTURE PARTNERS IX OVERAGE, L.P.

    ARCH VENTURE FUND IX, L.P.

    ARCH VENTURE FUND IX OVERAGE, L.P.

    CRANDELL KEITH

    BYBEE CLINTON

    • 10% Owner
    		 7,045,473 2021-03-31 0

    NELSEN ROBERT

    • Director
    • 10% Owner
    		 7,057,092 2021-03-31 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    WALSH KATHLEEN E - Director

    		2023-06-08 16:52:39 -0400 2033-06-06 A 16,532 a 16,532 direct

    BELLON CHRISTINE - Officer CHIEF LEGAL OFFICER

    		2023-11-22 16:05:11 -0500 2023-11-20 M 4,182 $7.22 a 86,584 direct yes -1.7189 -0.337 0.337 3 -5.3589 5

    BELLON CHRISTINE - Officer CHIEF LEGAL OFFICER

    		2023-11-22 16:05:11 -0500 2023-11-20 M 4,182 d 9,492 direct yes

    BELLON CHRISTINE - Officer CHIEF LEGAL OFFICER

    		2023-11-22 16:05:11 -0500 2023-11-20 S 5,000 $30.00 d 87,402 direct yes -1.7189 -0.337 0.337 3 -5.3589 5

    BELLON CHRISTINE - Officer CHIEF LEGAL OFFICER

    		2023-11-22 16:05:11 -0500 2023-11-20 S 5,000 $31.00 d 82,402 direct yes -1.7189 -0.337 0.337 3 -5.3589 5

    BELLON CHRISTINE - Officer CHIEF LEGAL OFFICER

    		2023-11-22 16:05:11 -0500 2023-11-20 M 5,818 $7.22 a 92,402 direct yes -1.7189 -0.337 0.337 3 -5.3589 5

    BELLON CHRISTINE - Officer CHIEF LEGAL OFFICER

    		2023-11-22 16:05:11 -0500 2023-11-20 M 5,818 d 10,918 direct yes

    SIMON AMY - Officer CHIEF MEDICAL OFFICER

    		2023-11-01 16:30:07 -0400 2023-10-30 S 3,448 $18.70 d 65,469 direct yes 14.2257 3.5914 16.5578 4 0.0 1

    CIARAMELLA GIUSEPPE - Officer PRESIDENT AND CSO

    		2023-10-24 16:05:04 -0400 2023-10-20 M 90,900 $0.67 a 139,150 direct 1.2927 8.7901 9.3071 5 -3.7229 3

    CIARAMELLA GIUSEPPE - Officer PRESIDENT AND CSO

    		2023-10-24 16:05:04 -0400 2023-10-20 M 90,900 d 60,005 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    BEAM THERAPEUTICS INC BEAM 2023-12-05 22:15:04 UTC 4.9272 0.3928 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 21:45:04 UTC 4.9272 0.3928 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 21:15:04 UTC 4.9272 0.3928 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 20:45:04 UTC 4.9272 0.3928 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 20:15:04 UTC 4.9272 0.3928 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 19:45:04 UTC 4.9272 0.3928 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 19:15:04 UTC 4.9272 0.3928 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 18:45:04 UTC 4.9272 0.3928 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 18:15:03 UTC 4.9272 0.3928 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 17:45:04 UTC 4.9272 0.3928 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 17:15:04 UTC 4.927 0.393 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 16:45:04 UTC 4.927 0.393 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 16:15:04 UTC 4.927 0.393 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 15:45:04 UTC 4.927 0.393 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 15:15:05 UTC 4.927 0.393 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 14:45:03 UTC 4.9255 0.3945 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 14:15:04 UTC 4.9255 0.3945 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 13:45:04 UTC 4.986 0.334 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 13:15:04 UTC 4.986 0.334 200000
    BEAM THERAPEUTICS INC BEAM 2023-12-05 12:45:05 UTC 4.986 0.334 200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Prudential Investment Portfolios 12- PGIM QMA Large-Cap Core Equity Plus Fund BEAM -900.0 shares, $-115839.0 2021-06-30 N-PORT
    Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio BEAM -6400.0 shares, $-556864.0 2021-09-30 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity Fund BEAM -466.0 shares, $-36883.9 2021-11-30 N-PORT
    Weiss Strategic Interval Fund- Weiss Strategic Interval Fund BEAM -1753.0 shares, $-83512.92 2022-09-30 N-PORT
    Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund BEAM -871.0 shares, $-26887.77 2023-07-31 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity ETF BEAM -2002.0 shares, $-46406.36 2023-08-31 N-PORT
    RBB Fund, Inc.- Boston Partners Long/Short Equity Fund BEAM -2517.0 shares, $-58344.06 2023-08-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments